公开(公告)号：US20250136946A1

公开(公告)日：2025-05-01

申请号：US18927121

申请日：2024-10-25

Applicant: Korea Research Institute of Chemical Technology

Inventor： Hyemin KIM ,  Han-Jin PARK ,  Ji-Woo KIM ,  Haneul NOH

IPC: C12N5/071 ,  G01N33/58

Abstract: The present disclosure relates to a real-time chemical screening method using hepatic organoids fluorescently labeled with cytochrome P450 1A1 enzyme. The method for screening an AHR modulator or a hazardous chemical using CYP1A1 fluorescently labelled human pluripotent stem cell line-derived hepatic organoids according to the present disclosure enables the detection of substances that induce CYP1A1 regulation with higher sensitivity than when using the conventional human pluripotent stem cell line-derived hepatocytes by using hepatic organoids that can mimic the human body, and thus can be usefully utilized for early screening of new toxic or carcinogenic compounds while replacing animal testing.

公开(公告)号：US20240141289A1

公开(公告)日：2024-05-02

申请号：US18547750

申请日：2021-04-21

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Han-Jin PARK ,  Hyemin KIM ,  Ilkyun IM ,  Ji-Woo KIM

IPC: C12N5/0735 ,  C12N5/00

CPC classification number: C12N5/0606 ,  C12N5/0018 ,  C12N2500/24

Abstract: The present invention relates to a method for constructing a human pluripotent stem cell-derived liver organoid having enhanced drug metabolic potentials and a liver organoid constructed by the method. Because differentiation is made from human induced pluripotent stem cells dedifferentiated from somatic cells of patients, the cells are easily supplied so that patient-specific liver organoids can be prepared. The organoids can similarly simulate the real human liver structure because they consist of hepatocytes, cholangiocytes, gallbladder cells, and microduct structures, have excellent expression and functions of drug metabolism enzymes, and exhibit drug toxicity, drug metabolic capability, and drug-induced cardiotoxicity. Thus, the organoids can be advantageously used as liver models for searching for pathogenesis of liver diseases and for evaluating drug stability.

公开(公告)号：US20230235294A1

公开(公告)日：2023-07-27

申请号：US18010932

申请日：2021-03-19

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Han-Jin PARK ,  Ji-Woo KIM ,  Ilkyun IM ,  Hyemin KIM

IPC: C12N5/074

CPC classification number: C12N5/0696 ,  C12N2503/02 ,  C12N2510/00

Abstract: The present invention relates to a human induced pluripotent stem cell line transformed with fluorescent protein-tagged CYP1A1 and an AHR modulator screening method using the same. Specifically, a human-induced pluripotent stem cell line (hiPSC line) in which a gene was edited to express a cytochrome P450 1A1 (CYP1A1) protein in a state of fusion with a fluorescent protein without inhibiting its unique function was prepared, and it was confirmed that an AHR modulator could be screened by screening cells in a living state using the cell line-derived liver cells better than in the case of using existing human primary hepatocytes (hPH) or HepG2 cells. Therefore, the CYP1A1-mCherry hiPSC cell line of the present invention can be effectively used for screening AHR modulating compounds.